Costs of type 2 diabetes in Germany -: Results of the CODE-2® Study
Costs of type 2 diabetes in Germany -: Results of the CODE-2® Study
复制标题
DOI：
10.1055/s-2001-14102
复制
发表时间：
2001-05-18
影响因子：
0.6
通讯作者：
Görtz, A
中科院分区：
文献类型：
--
作者：
Liebl, A;Neiss, A;Görtz, A
背景和目的：糖尿病是一种日益增加和广泛的慢性疾病，给卫生保健系统造成相当大的费用。在CODE-2（R）研究（欧洲2型糖尿病的费用）中，第一次评估和分析了德国2型糖尿病患者的总费用。在这项研究的德国分支中，通过与135名医生的面对面访谈，回顾性地获得了809名患者的医疗，人口统计学和经济数据。这些结果预计为2型糖尿病患者的总人口在德国。结果：2型糖尿病患者在德国在1998年造成的年度费用达314亿DM。这些费用的大部分（61%）由法定和私人健康保险支付。这些患者的法定健康保险（SHI）年度费用达18,5亿马克。这些费用分为50%用于住院治疗，13%用于门诊护理，27%用于药物治疗。糖尿病药物（胰岛素、口服降糖药）仅占SHI总成本的7%。所有糖尿病患者中只有26%调整为HbA 1c值
Background and Objective: Diabetes is an increasing and widespread chronic disease causing considerable costs for the health care system. In the CODE-2(R) Study (Costs of Diabetes in Europe - Type 2) the total expenses for type 2 diabetics in Germany were evaluated and analyzed for the first time.Patients and Methods: The CODE-2(R)-study has been performed in eight European countries. In the German arm of the study, medical, demographic, and economic data of 809 patients were obtained retrospectively for a one year period, using face-to-face interviews with 135 physicians. These results were projected for the overall population of type 2 diabetes patients in Germany.Results: The annual costs caused by type 2 diabetes patients in Germany in 1998 amount to 31.4 billion DM. The majority of these costs (61 %) were covered by statuatory and private health insurance. The annual expenses of the statuatory Health Insurance (SHI) for these patients amounted to 18,5 billion DM. These costs divided in 50% spent for inpatient treatment, 13% for ambulatory care, and 27% for medication. Diabetes medication (Insulin, oral antidiabetic drugs) accounted for only 7% of total SHI costs. Only 26% of all diabetic patients were adjusted to HbA1c values